



August 5, 2022

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

**Sub.: Submission of copies of published Unaudited Consolidated Financial Results**

In continuation of our letter dated August 2, 2022, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2022 published on August 3, 2022 in MINT (English) and HINDUSTAN (Hindi).

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624

**Jammu & Kashmir Infrastructure Development Finance Corporation Ltd.**  
(A Government of Jammu and Kashmir Undertaking)  
Regd. Office: Office of DG Accounts and Treasuries,  
Government of J&K, Muthi, TalabTiloo, Jammu 180001 J&K  
Branch: Finance Department, Government of J&K, Civil Secretariat, Srinagar  
(May-Oct)/Jammu (Nov-Apr) J&K  
Phone: +91 194 2506061+91 191 2544137 | <http://www.jkidfc.in>

**EXPRESSION OF INTEREST  
NIT No. 09-JKIDFC of 2022**

Jammu and Kashmir Infrastructure Development Finance Corporation (JKIDFC) Ltd. is a Registered Corporation under the Companies Act, 2013. The Corporation is mandated to raise loan upto Rs. 8,000.00 crore for funding Infrastructure Development in Jammu and Kashmir. The loans to be raised by the Corporation are guaranteed by the following dedicated Revenue Streams:

- Revision of taxes under the Jammu and Kashmir (Motor Spirit and Diesel Oil) (Taxation of Sales) Act by revising rate of tax on sale of diesel from 16% minus Rs. 2.5 per litre to 16% minus Rs. 0.5 per litre.
- Increase in one time road tax at 9% for motor vehicles.
- Increasing efficiency of collection of water connection charges by way of covering all the unregistered consumers and improving collection efficiency to 100%.
- Increasing revenue realization by making full use of permissible limit of 80 lakh cft of extraction of timber."

2. The repayment of the principle and interest shall be made directly through the designated account from the revenues accrued from the above dedicated streams. The duration of loan would be of 15 years.

3. Sealed Expression of Interest (EOI) is being invited from reputed RBI regulated Banking and Financial Institutions/Companies of the country, to submit written proposals for advancing loans of **Rs. 1000 crore** to be availed during remaining months of the current financial year 2022-23. The bidders have to quote the rate of interest (MCLR linked) at which they will offer the loan along with the amount they are prepared to invest during 2022-23. Any change in the interest rate during subsequent years will be MCLR linked.

4. Expression of Interest (EOI) must be delivered both in written hard copy and as well as digital form and should include the banking/ financial company's demonstrated capacity to provide the credit facility. The hard copy of EOI shall be delivered through registered post/ speed post/ courier/ by hand latest by **August 24th 2022 (Wednesday) up to 1700 hrs IST** on the below mentioned address. The same shall be opened on next working day i.e. **August 25th 2022 (Thursday) at 1700 hrs IST.**

**Director Finance,  
Jammu & Kashmir Infrastructure Development Finance Corporation - JKIDFC,  
Room No. 421, 4th Floor,  
New Civil Secretariat, Srinagar -190001,  
Phone: 0194-2506201,  
Mobile No.: 9419205227,  
Email: [caofinance-jk@nic.in](mailto:caofinance-jk@nic.in)**

5. The instructions for bidders and tender documents are available on the official website of JKIDFC @ [www.sims-jk.gov.in/jkidfc](http://www.sims-jk.gov.in/jkidfc). **Queries**, if any, can also be clarified through our official mail support [dfc@jk.gov.in](mailto:dfc@jk.gov.in).

6. The terms and conditions governing EOI shall be as under:

- Interest and Principle would be paid for respective period to the selected Banks/ Institutions as per the agreement executed and in line with the RBI guidelines.
- The funds have to be disbursed in installments or in full, as per requirement and agreed terms & conditions and after execution of necessary documents with the Jammu and Kashmir Infrastructure Development Finance Corporation (JKIDFC) Ltd.
- The Jammu and Kashmir Infrastructure Development Finance Corporation (JKIDFC) Ltd. reserves the right to make repayment of the loan at an early date at its discretion which would not attract any penal interest/ charges, etc.
- Selection criteria for the bid shall be the lowest rate of interest and other charges, if any.
- There shall be no commitment charges.
- Successful bidder will have to disburse the required amount within 15 days from the date of the demand, from time to time, as per requirement of the Corporation at very short notices.
- If a bidder, whose offer has been accepted, fails to disburse the required amount within 15 days from the demand, the requisite time frame, loss incurred, if any to JKIDFC, shall be borne by the Financial Institution concerned and shall be recovered by way of adjustment from the dues towards loan servicing.
- The Hon'ble High court at Jammu and Kashmir shall have exclusive jurisdiction to adjudicate the disputes arising out of the agreement, if any.
- The bidder can quote rate for more than Rs. 1000 crore on the same rates and terms & conditions.
- The Jammu and Kashmir Infrastructure Development Finance Corporation (JKIDFC) Ltd. reserves the right to terminate a bid without assigning any reason thereof.

No. FD-vii-Gen (203) JKIDFC/2018/283  
Dated: 02.08.2022 (Showkat Hussain Mir)  
DIPK-NB-2927-22 Director Finance, JKIDFC Ltd.

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022						
(Rs. in Crores except per share data)						
Particulars	Standalone			Consolidated		
	3 months ended 30.06.2022	3 months ended 30.06.2021	Year ended 31.03.2022	3 months ended 30.06.2022	3 months ended 30.06.2021	Year ended 31.03.2022
	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
1. Total income from operations (net)	12.80	158.25	202.06	3,275.89	5,943.14	31,187.58
2. Net Profit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2.83	137.94	147.08	80.39	84.37	388.65
3. Net Profit/(loss) for the period before tax (after Exceptional and/or Extraordinary items)	2.83	137.94	147.08	80.39	84.37	388.65
4. Net Profit/(loss) for the period after tax (after Exceptional and/or Extraordinary items)	1.76	97.52	102.62	68.48	35.81	318.40
5. Total comprehensive income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	1.75	97.53	102.98	54.53	30.59	306.49
6. Paid-up equity share capital (Face Value Rs. 2 Per Share)	69.02	69.02	69.02	69.02	69.02	69.02
7. Reserves excluding revaluation reserve as per balance sheet of previous accounting year	-	-	6,680.57	-	-	3,865.59
8. Earnings per share (of Rs. 2 each) (not annualised)						
a) Basic (Rs.)	0.05	2.83	2.97	1.63	0.61	7.34
b) Diluted (Rs.)	0.05	2.83	2.97	1.63	0.61	7.34

**Note:**  
The above is an extract of the detailed format of financial results for the quarter ended June 30, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. The full format of the quarter ended Financial Results are available on the Stock Exchange website, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.maxfinancialservices.com](http://www.maxfinancialservices.com).

Date: August 1, 2022  
Place: Goa

By Order of the Board  
**Mohit Talwar**  
Managing Director  
DIN : 02394694

Jubilant Pharmova Limited				
Regd. Office: Bhartiagram, Gajraula, District Amroha - 244 223 (U.P.)   CIN : L24116UP1978PLC004624 Website: <a href="http://www.jubilantpharmova.com">www.jubilantpharmova.com</a>   Email: <a href="mailto:investors@jubil.com">investors@jubil.com</a>   Tel: +91-5924-267437				
Extract of Unaudited Financial Results for the Quarter ended 30 June 2022				
Consolidated Unaudited Financial Results				
(₹ in Lakhs)				
Particulars	Quarter Ended		Year Ended	
	30 June	31 March	30 June	31 March
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2022	2022	2021	2022
Total income from operations	145172	152753	163465	613016
Net profit before tax and exceptional items	6906	10567	24651	63045
Net profit before tax (after exceptional items)	6906	10567	24651	63045
Net profit after tax and exceptional items	4675	5909	16049	41302
Total comprehensive income after tax (comprising profit for the period after tax and other comprehensive income after tax)	16260	13166	31561	65698
Equity share capital	1592	1592	1592	1592
Reserves excluding revaluation reserves (other equity)				530264
Earnings per share of ₹ 1 each-Not annualized				
Basic (₹)	2.96	3.74	10.09	26.00
Diluted (₹)	2.96	3.74	10.09	26.00

  

Standalone Unaudited Financial Results				
(₹ in Lakhs)				
Particulars	Quarter Ended		Year Ended	
	30 June	31 March*	30 June*	31 March*
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2022	2022	2021	2022
Total income from operations	20457	24069	17864	72573
Net (loss)/profit before tax and exceptional items	(649)	1533	(99)	8472
Net (loss)/profit before tax (after exceptional items)	(649)	1533	(99)	8472
Net (loss)/profit after tax and exceptional items	(518)	1046	(76)	8049
Total comprehensive (loss)/income after tax (comprising (loss)/profit for the period after tax and other comprehensive income after tax)	(499)	1118	(82)	8107
Equity share capital	1593	1593	1593	1593
Reserves excluding revaluation reserves (other equity)				242314
Earnings per share of ₹ 1 each-Not annualized				
Basic (₹)	(0.33)	0.66	(0.05)	5.05
Diluted (₹)	(0.33)	0.66	(0.05)	5.05

\*refer note 1

**Notes:**

- During the quarter ended 30 June 2022, the Scheme of Arrangement ("the Scheme") for demerger of the Active Pharmaceuticals Ingredients ("API") business undertaking of Jubilant Generics Limited ("JGL"), an indirect wholly owned subsidiary of the Company, and vesting of the same with the Company, on a going concern basis, with Appointed Date of 1 April 2022 was approved by Hon'ble National Company Law Tribunal, Allahabad Bench ("NCLT") vide its order dated 13 June 2022. The said NCLT order was filed with the Registrar of Companies by the Company and JGL on 1 July 2022 thereby making the Scheme effective from that date. As a result, all assets and liabilities of the API business undertaking vested into the Company were recorded at the respective book values appearing in the books of account of JGL as at 1 April 2022 and the difference amounting to ₹ 115725 lakhs (total assets of ₹ 139478 less total liabilities of ₹ 23753) after considering the cancellation of inter-company balances has been accounted within "Other Equity".  
Further, the financial results for the quarters ended 31 March 2022 and 30 June 2021 and for the year ended 31 March 2022 have been restated to include the financial information in respect of prior periods as if the demerger of API business undertaking of JGL and vesting of the same with the Company had occurred from the beginning of the preceding period in the financial results, irrespective of the Appointed Date of the demerger, in accordance with the requirements of Ind AS 103 "Business Combinations".
- The consolidated and the standalone unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 02 August 2022.
- The above is an extract of the detailed format of the consolidated and the standalone unaudited financial results for the quarter ended 30 June 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and the standalone unaudited financial results for the quarter ended 30 June 2022 is available under Investors section of our website at [www.jubilantpharmova.com](http://www.jubilantpharmova.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Jubilant Pharmova Limited  
**Hari S. Bhartia**  
Co-Chairman & Managing Director

Place : Noida  
Date : 02 August 2022

**As nutritious as soup.  
And just as easy to digest.**

**Easynomics**  
A Weekly newsletter by Vivek Kaul

- Covers big economic issues
- Focuses on impact on daily lives
- Complimentary for limited time



To subscribe, scan this code or login:  
[livemint.com/newsletters](http://livemint.com/newsletters)

Download the Mint app now.

